These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 33390340

  • 41. Commentary on: "Inherited DNA-repair gene mutations in men with metastatic prostate cancer." Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016 Aug 4;375(5):443-53.
    Lee BH.
    Urol Oncol; 2017 Sep; 35(9):575-576. PubMed ID: 28789927
    [Abstract] [Full Text] [Related]

  • 42. Germline and somatic mutations in prostate cancer: Implications for treatment.
    Chalker C, Chun B, Sokolova AO.
    Curr Probl Cancer; 2024 Jun; 50():101101. PubMed ID: 38718711
    [Abstract] [Full Text] [Related]

  • 43. Germline testing and genetic counselling in prostate cancer.
    Russo J, Giri VN.
    Nat Rev Urol; 2022 Jun; 19(6):331-343. PubMed ID: 35449224
    [Abstract] [Full Text] [Related]

  • 44. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013.
    Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N, European Association of Urology.
    Eur Urol; 2014 Jan; 65(1):124-37. PubMed ID: 24207135
    [Abstract] [Full Text] [Related]

  • 45. Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial.
    Shore N, Gazi M, Pieczonka C, Heron S, Modh R, Cahn D, Belkoff LH, Berger A, Mazzarella B, Veys J, Idom C, Morris D, Jayram G, Engelman A, Bukkapatnam R, Dato P, Bevan-Thomas R, Cornell R, Wise DR, Hardwick MK, Hernandez RD, Rojahn S, Layman P, Hatchell KE, Heald B, Nussbaum RL, Nielsen SM, Esplin ED.
    Eur Urol Oncol; 2023 Oct; 6(5):477-483. PubMed ID: 37574391
    [Abstract] [Full Text] [Related]

  • 46. Germline Testing for Prostate Cancer Prognosis: Implications for Active Surveillance.
    Helfand BT, Xu J.
    Urol Clin North Am; 2021 Aug; 48(3):401-409. PubMed ID: 34210494
    [Abstract] [Full Text] [Related]

  • 47. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N.
    Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
    [Abstract] [Full Text] [Related]

  • 48. Germline Mutations and Ancestry in Prostate Cancer.
    Bataba E, Babcock K, Isensee KA, Eldhose B, Kohaar I, Chesnut GT, Dobi A.
    Curr Oncol Rep; 2024 Feb; 26(2):175-180. PubMed ID: 38265515
    [Abstract] [Full Text] [Related]

  • 49. Prevalence of comprehensive DNA damage repair gene germline mutations in Chinese prostate cancer patients.
    Wu J, Wei Y, Pan J, Jin S, Gu W, Gan H, Zhu Y, Ye DW.
    Int J Cancer; 2021 Feb 01; 148(3):673-681. PubMed ID: 33006389
    [Abstract] [Full Text] [Related]

  • 50. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
    Matveev VB, Kirichek AA, Filippova MG, Savinkova AV, Khalmurzaev OA, Lyubchenko LN.
    Urologiia; 2019 Dec 01; (5):79-85. PubMed ID: 31808637
    [Abstract] [Full Text] [Related]

  • 51. Germline genetics in localized prostate cancer.
    Ryan ST, Nguyen V, Bree KK, Holst DD, Kader AK.
    Curr Opin Urol; 2019 Jul 01; 29(4):326-333. PubMed ID: 31116139
    [Abstract] [Full Text] [Related]

  • 52. Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients.
    Wei Y, Wu J, Gu W, Qin X, Dai B, Lin G, Gan H, Freedland SJ, Zhu Y, Ye D.
    Eur Urol; 2019 Sep 01; 76(3):280-283. PubMed ID: 31248605
    [Abstract] [Full Text] [Related]

  • 53. Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer.
    Wu Y, Yu H, Li S, Wiley K, Zheng SL, LaDuca H, Gielzak M, Na R, Sarver BAJ, Helfand BT, Walsh PC, Lotan TL, Cooney KA, Black MH, Xu J, Isaacs WB.
    Eur Urol Oncol; 2020 Apr 01; 3(2):224-230. PubMed ID: 31948886
    [Abstract] [Full Text] [Related]

  • 54. Genetically Informed Prostate Cancer Treatment for Metastatic Disease.
    Siebert AL, Szymaniak BM, Numan Y, Morgans AK.
    Urol Clin North Am; 2021 Aug 01; 48(3):365-371. PubMed ID: 34210491
    [Abstract] [Full Text] [Related]

  • 55. Inherited Mutations in Men Undergoing Multigene Panel Testing for Prostate Cancer: Emerging Implications for Personalized Prostate Cancer Genetic Evaluation.
    Giri VN, Obeid E, Gross L, Bealin L, Hyatt C, Hegarty SE, Montgomery S, Forman A, Bingler R, Kelly WK, Dicker AP, Winheld S, Trabulsi EJ, Chen DYT, Lallas CD, Allen BA, Daly MB, Gomella LG.
    JCO Precis Oncol; 2017 May 01; 1():. PubMed ID: 34164591
    [Abstract] [Full Text] [Related]

  • 56. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
    Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, van der Kwast TH, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea-Lager DE, van der Poel HG, Rouvière O, Schoots IG, Tilki D, Wiegel T, Willemse PM, Cornford P.
    Eur Urol; 2021 Feb 01; 79(2):243-262. PubMed ID: 33172724
    [Abstract] [Full Text] [Related]

  • 57. Germline testing in those at risk of prostate cancer.
    Carroll PR, Witte JS, Parsons JK.
    Can J Urol; 2019 Oct 01; 26(5 Suppl 2):31-33. PubMed ID: 31629425
    [Abstract] [Full Text] [Related]

  • 58. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
    Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, der Kwast THV, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea-Lager DE, der Poel HGV, Rouvière O, Schoots IG, Tilki D, Wiegel T, Willemse PM, Mottet N.
    Eur Urol; 2021 Feb 01; 79(2):263-282. PubMed ID: 33039206
    [Abstract] [Full Text] [Related]

  • 59. Germline pathogenic variants in unselected Korean men with prostate cancer.
    So MK, Ahn HK, Huh J, Kim KH.
    Investig Clin Urol; 2022 May 01; 63(3):294-300. PubMed ID: 35534218
    [Abstract] [Full Text] [Related]

  • 60. Incorporating Genetic Risk Into Prostate Cancer Care: Implications for Early Detection and Precision Oncology.
    Amini AE, Salari K.
    JCO Precis Oncol; 2024 Feb 01; 8():e2300560. PubMed ID: 38412389
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.